Drugs / JS401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06041165 | Aug 2023 → Jun 2024 | hyperlipidemia | Shanghai Junshi Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06041165 ↗ |
| Route | Subcutaneous | “by subcutaneous (sc) injections” NCT06041165 ↗ |